Literature DB >> 8595502

The role of viral diversity in HIV pathogenesis.

J Goudsmit1.   

Abstract

From the time of seroconversion, patients who retain a high viral load are known to progress more rapidly to AIDS than individuals who have lower levels of HIV. Increased viral load is accompanied by decreasing CD4 cell numbers, and CD4 cell counts are therefore widely used as a diagnostic marker or predictor of progression in HIV patients. During the asymptomatic phase, however, CD4 counts often remain in the "normal" range, and this marker provides little information on potential disease progression. A shift in viral phenotype from non-syncytium-inducing (NSI) to syncytium-inducing (SI) heralds disease progression, and early in infection SI progression can be distinguished from nonprogression on the basis of CD4 changes. NSI progression, on the other hand, cannot be distinguished from nonprogression on the basis of CD4 counts but can be distinguished on the basis of RNA load. Molecular assessment of viral phenotype, such as quantitative measures of HIV RNA, as well as syncytium-inducing and nonsyncytium-inducing is therefore able to provide valuable information on the probable course of progression in individual patients, thus aiding in more effective disease management.

Entities:  

Mesh:

Year:  1995        PMID: 8595502

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  9 in total

1.  Do beta-chemokines have clinical relevance in HIV infection?

Authors:  C E Mackewicz; E Barker; G Greco; G Reyes-Teran; J A Levy
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

2.  Viral entry through CXCR4 is a pathogenic factor and therapeutic target in human immunodeficiency virus type 1 disease.

Authors:  B Schramm; M L Penn; R F Speck; S Y Chan; E De Clercq; D Schols; R I Connor; M A Goldsmith
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue.

Authors:  M L Penn; J C Grivel; B Schramm; M A Goldsmith; L Margolis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

4.  Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism.

Authors:  K Kato; H Sato; Y Takebe
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

5.  Movements of HIV-1 genomic RNA-APOBEC3F complexes and PKR reveal cytoplasmic and nuclear PKR defenses and HIV-1 evasion strategies.

Authors:  Mariana Marin; Sheetal Golem; Susan L Kozak; David Kabat
Journal:  Virus Res       Date:  2015-11-25       Impact factor: 3.303

6.  Presence of host ICAM-1 in laboratory and clinical strains of human immunodeficiency virus type 1 increases virus infectivity and CD4(+)-T-cell depletion in human lymphoid tissue, a major site of replication in vivo.

Authors:  Salim Bounou; Jacques E Leclerc; Michel J Tremblay
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

7.  Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop.

Authors:  R F Speck; K Wehrly; E J Platt; R E Atchison; I F Charo; D Kabat; B Chesebro; M A Goldsmith
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

8.  Rabbit cells expressing human CD4 and human CCR5 are highly permissive for human immunodeficiency virus type 1 infection.

Authors:  R F Speck; M L Penn; J Wimmer; U Esser; B F Hague; T J Kindt; R E Atchison; M A Goldsmith
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  STRL33, A novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1.

Authors:  F Liao; G Alkhatib; K W Peden; G Sharma; E A Berger; J M Farber
Journal:  J Exp Med       Date:  1997-06-02       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.